Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
3(25%)
Results Posted
200%(6 trials)
Terminated
4(33%)

Phase Distribution

Ph phase_2
9
75%
Ph phase_3
2
17%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

9

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
9(75.0%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

3 of 9 finished

Non-Completion Rate

66.7%

6 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(3)
Terminated(6)

Detailed Status

Terminated4
Completed3
Active, not recruiting2
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
42.9%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 29 (75.0%)
Phase 32 (16.7%)

Trials by Status

active_not_recruiting217%
completed325%
recruiting18%
terminated433%
withdrawn217%

Recent Activity

3 active trials
Showing 5 of 12
active_not_recruitingphase_2

Monthly Dosing of Atacicept in IgAN

NCT07020923
recruitingphase_2

Atacicept in Multiple Glomerular Diseases

NCT06983028
active_not_recruitingphase_3

Atacicept in Subjects With IgA Nephropathy

NCT04716231
withdrawnphase_3

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

NCT05609812
completedphase_2

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

NCT00664521
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07020923Phase 2

Monthly Dosing of Atacicept in IgAN

Active Not Recruiting
NCT06983028Phase 2

Atacicept in Multiple Glomerular Diseases

Recruiting
NCT04716231Phase 3

Atacicept in Subjects With IgA Nephropathy

Active Not Recruiting
NCT05609812Phase 3

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Withdrawn
NCT00664521Phase 2

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

Completed
NCT00642902Phase 2

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

Terminated
NCT00573157Phase 2

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Terminated
NCT00430495Phase 2

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

Completed
NCT00595413Phase 2

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Completed
NCT00624468Phase 2

Atacicept in Subjects With Optic Neuritis

Terminated
NCT01369628Phase 1

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Terminated
NCT01440231Phase 2

Atacicept Demonstrating Dose RESponSe

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12